Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 18/20 | 0.42 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969695 | 0.95 | HDAC1 (0.48) | HDAC1HDAC6NPY5R | |
| SCHEMBL26969707 | 0.82 | TSHR (0.38) | HDAC1HDAC6NPY5R | |
| SCHEMBL26969745 | 0.81 | HDAC1 (0.41) | HDAC1HDAC6NPY5R | |
| SCHEMBL25238614 | 0.80 | NOTUM (0.42) | HDAC1HDAC6NPY5R | |
| SCHEMBL26969727 | 0.79 | NPY5R (0.42) | NPY5R | |
| SCHEMBL26969782 | 0.79 | NOTUM (0.41) | HDAC1HDAC6NPY5R | |
| SCHEMBL25231173 | 0.78 | NPY5R (0.38) | NPY5RNPC1L1 | |
| SCHEMBL26969766 | 0.78 | NPY5R (0.38) | NPY5R | |
| SCHEMBL25232157 | 0.78 | NPY5R (0.41) | NPY5R | |
| SCHEMBL26969777 | 0.77 | HTR6 (0.40) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | HDAC1 2067/4885HDAC6 526/4885NPY5R 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.